

Table S6. Best overall response by lesion type (safety analysis set).

	Patients with response, n (%) [95% confidence interval]			
	Stratum 1 (n=16)	Stratum 2 (n=8)	Stratum 3 (n=2)	Overall (n=26)
Target lesions				
CR	1 (6.3) [0.16, 30.23]	0 [0.00, 36.94]	0 [0.00, 84.19]	1 (3.8) [0.10, 19.64]
PR	0 [0.00, 20.59]	0 [0.00, 36.94]	0 [0.00, 84.19]	0 [0.00, 13.23]
SD	10 (62.5) [35.43, 84.80]	4 (50.0) [15.70, 84.30]	1 (50.0) [1.26, 98.74]	15 (57.7) [36.92, 76.65]
PD	3 (18.8) [4.05, 45.65]	2 (25.0) [3.19, 65.09]	1 (50.0) [1.26, 98.74]	6 (23.1) [8.97, 43.65]
NE	2 (12.5) [1.55, 38.35]	2 (25.0) [3.19, 65.09]	0 [0.00, 84.19]	4 (15.4) [4.36, 34.87]
Non-target lesions				
CR	1 (6.3) [0.16, 30.23]	0 [0.00, 36.94]	0 [0.00, 84.19]	1 (3.8) [0.10, 19.64]
Non-CR/non-PD	10 (62.5) [35.43, 84.80]	6 (75.0) [34.91, 96.81]	1 (50.0) [1.26, 98.74]	17 (65.4) [44.33, 82.79]
PD	4 (25.0) [7.27, 52.38]	1 (12.5) [0.32, 52.65]	1 (50.0) [1.26, 98.74]	6 (23.1) [8.97, 43.65]
NE	1 (6.3) [0.16, 30.23]	1 (12.5) [0.32, 52.65]	0 [0.00, 84.19]	2 (7.7) [0.95, 25.13]

Non-CR/non-PD: persistence of one or more non-target lesion(s) or/and maintenance of tumor markers (carcinoembryonic antigen, cytokeratin fragment 21-1) above the normal limits.

Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease